On September 3, 2024, Kangfang Biotechnology (Cayman) Ltd. submitted its latest monthly securities change report to the Hong Kong Exchanges and Clearing Limited, reporting on the company's share changes as of August 31, 2024. The report shows that the company's authorized/registered capital and issued shares (excluding treasury shares) remained unchanged during the reporting period, at 5,000,000,000 ordinary shares with a par value of $0.00001 per share and a total registered capital of $50,000; the total number of issued shares is 865,857,176. In addition, under the stock options plan adopted by the company on June 28, 2022, the number of share options decreased from 436,000 to 394,000 this month, a decrease of 42,000 share options, so there were no new share issuances. There were no changes to other share issuance plans such as convertible bonds and restricted share unit plans. The report was submitted by Director Xia Yu.

On September 3, 2024, Kangfang Biotechnology (Cayman) Ltd. submitted its latest monthly securities change report to the Hong Kong Exchanges and Clearing Limited, reporting on the company's share changes as of August 31, 2024. The report shows that the company's authorized/registered capital and issued shares (excluding treasury shares) remained unchanged during the reporting period, at 5,000,000,000 ordinary shares with a par value of $0.00001 per share and a total registered capital of $50,000; the total number of issued shares is 865,857,176. In addition, under the stock options plan adopted by the company on June 28, 2022, the number of share options decreased from 436,000 to 394,000 this month, a decrease of 42,000 share options, so there were no new share issuances. There were no changes to other share issuance plans such as convertible bonds and restricted share unit plans. The report was submitted by Director Xia Yu.